Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) – Equities researchers at HC Wainwright issued their Q1 2025 ...

Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a ...

A federal court in Massachusetts found in favor of Pfizer, whose oral Covid-19 treatment Paxlovid survived a patent challenge ...

Nearing five years since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, scientists continue to uncover the risk factors of blood clots and potential death for hospitalized and ...

Enanta Pharmaceuticals (ENTA) announced the United States District Court of Massachusetts has issued a ruling on a summary judgment ...

Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosing of the first patient in the Phase I ...

Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of Massachusetts ruled that Pfizer ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule ...

Enanta Pharmaceuticals (NETA) stock fell as the company plans to appeal a court ruling favoring Pfizer in a patent dispute over COVID-19 pill Paxlovid. Read more here.

H.C. Wainwright analyst Ed Arce has maintained their bullish stance on ENTA stock, giving a Buy rating on December 13.Don't Miss Our Christmas ...

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Enanta Pharma ENTA in the last three months. The following table provides a quick overview of ...

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the ...